Bioluminescent Analyte Detection with Lumit™ Immunoassays

This webinar is Part 1 of the Lumit™ Technology Webinar Series. 

In this webinar, you will learn:

  • How bioluminescent technology enables no-wash immunoassays
  • How to apply different formats of Lumit™ immunoassays to detect a variety of analytes
  • Specific examples of immunoassays to detect cytokines important in T-cell biology and inflammation


Lumit™ Technology Webinar Series

Immunoassays are an essential tool for life science researchers, widely used for decades. Applying bioluminescent technology to this well-accepted assay format to create Lumit™ Immunoassays has made analyte detection faster and easier than ever before. This webinar series will introduce you to Lumit™ Immunoassay technology and highlight key research areas where bioluminescent immunoassays have supported research discoveries.

Part 1: Bioluminescent Analyte Detection with Lumit™ Immunoassays

In the first part of this series, we will introduce Lumit™  technology, a novel bioluminescent immunoassay platform, and how the technology can be applied to a variety of assay formats. Dr. Dan Lazar from Promega will describe how bioluminescence makes immunoassays faster and easier, and how you can apply this technology to your research needs.

Other Webinars in this Series:

Using Lumit™ Technology to Address Inflammasome-mediated Cytokine Release

Ask the Experts Forum: Implementing Lumit™ Immunoassays

Advances in Glucagon Detection Supporting Diabetes and Metabolic Disorder Research

Optimizing IL-6 Detection for High-Throughput Screening



Dan Lazar, PhD
Senior Research Scientist

Dr. Dan Lazar received his Ph.D. in biological chemistry from the University of Michigan and then completed a postdoctoral fellowship focused on cell signaling at Warner Lambert/Parke-Davis. Subsequently, he was a Team Leader and Senior Scientist at Eli Lilly within the metabolic disease drug-discovery area for well over a decade where he gained extensive experience in the development, validation and implementation of cell-based and biochemical assays for drug discovery. As a Group Leader and Senior Research Scientist at Promega, Dan and his colleagues are principally focused on delivering novel cell-based assays for the quantitative assessment of various aspects of cell health to assist academic and industrial investigators.